首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NKTR |
| Uniprot No | P30414 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 10-175aa |
| 氨基酸序列 | HFDIEINREPVGRIMFQLFSDICPKTCKNFLCLCSGEKGLGKTTGKKLCYKGSTFHRVVKNFMIQGGDFSEGNGKGGESIYGGYFKDENFILKHDRAFLLSMANRGKHTNGSQFFITTKPAPHLDGVHVVFGLVISGFEVIEQIENLKTDAASRPYADVRVIDCGV |
| 预测分子量 | 34.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NKTR重组蛋白(如NKTR-214)的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Phase I Dose-Escalation Study of NKTR-214. a CD122-Biased Cytokine, in Patients (Pts) with Advanced Solid Tumors*
**作者**：Diab A, et al.
**摘要**：该I期临床试验评估了NKTR-214(一种IL-2受体激动剂重组蛋白)在晚期实体瘤患者中的安全性和初步疗效。结果显示，药物通过选择性激活CD8+ T细胞和自然杀伤细胞，表现出可控的毒性和抗肿瘤活性，部分患者实现持久缓解。
---
2. **文献名称**：*NKTR-214 Combined with Nivolumab in Patients with Advanced Melanoma: Efficacy and Safety from the Phase 1/2 PIVOT-02 Study*
**作者**：Weber JS, et al.
**摘要**：研究探讨了NKTR-214联合PD-1抑制剂nivolumab治疗晚期黑色素瘤的效果。结果显示联合疗法显著提高客观缓解率(ORR)，并增强肿瘤微环境中的免疫细胞浸润，支持其作为潜在免疫联合治疗策略。
---
3. **文献名称**：*Design of a First-in-Class Cytokine Drug Conjugate (CDC) for Targeted Immune Activation*
**作者**：Charych D, et al.
**摘要**：本文阐述了NKTR-214的设计原理，通过聚乙二醇化重组IL-2优化其药代动力学，延长半衰期并减少毒性。临床前数据表明，该重组蛋白可选择性激活效应T细胞，而非调节性T细胞，从而增强抗肿瘤免疫应答。
---
4. **文献名称**：*Biomarker Analysis from a Phase II Study of NKTR-214 plus Nivolumab in Renal Cell Carcinoma*
**作者**：Sharma P, et al.
**摘要**：该II期研究分析了NKTR-214联合nivolumab在肾细胞癌中的生物标志物。结果显示，治疗显著增加肿瘤内CD8+ T细胞密度及干扰素-γ信号，且生物标志物阳性患者无进展生存期(PFS)更长，验证了其免疫调节机制。
---
以上文献聚焦于NKTR-214的机制、临床疗效及联合治疗潜力，涵盖I/II期试验数据及分子设计优化。
**Background of NKTR Recombinant Proteins**
NKTR recombinant proteins represent a class of engineered biologics designed to enhance therapeutic efficacy through structural modifications, particularly *PEGylation* (polyethylene glycol conjugation). Developed by Nektar Therapeutics, this technology aims to improve pharmacokinetics, prolong drug half-life, and reduce immunogenicity compared to native proteins. The core innovation lies in site-specific attachment of PEG chains to recombinant proteins, enabling controlled release and optimized bioactivity.
Historically, traditional PEGylation methods often led to random conjugation, which could impair protein function or trigger immune responses. NKTR’s approach addresses these limitations by utilizing multi-arm PEG polymers and reversible linkers. For example, NKTR-214 (bempegaldesleukin), an IL-2 receptor agonist, incorporates six releasable PEG chains that gradually shed in vivo, restoring cytokine activity while maintaining sustained exposure. This design balances immune activation and tolerability, making it suitable for oncology applications.
NKTR platforms have been applied to various therapeutic areas, notably immuno-oncology. By modifying cytokines (e.g., IL-2. IL-15) or antibody fragments, these proteins enhance tumor-targeted immune responses. Clinical trials explore combinations with checkpoint inhibitors (e.g., anti-PD-1), leveraging synergistic effects to improve antitumor efficacy. Additionally, NKTR technology extends to pain management (e.g., NKTR-181. a slow-release opioid) and rare diseases, showcasing its versatility.
Despite promise, challenges remain, including manufacturing complexity and potential PEG-related toxicity. However, partnerships with pharmaceutical giants (e.g., Bristol-Myers Squibb) underscore confidence in its clinical potential. As of 2023. multiple NKTR-based candidates are in mid-to-late-stage trials, reflecting a growing interest in precision-engineered biologics for personalized medicine.
In summary, NKTR recombinant proteins exemplify advancements in protein engineering, aiming to bridge the gap between biologic potency and therapeutic practicality.
×
